Abstracts tagged "T Cell"

Abstract Number: 0889 • ACR Convergence 2025
Potentially pathogenic memory CD4 T cells with a B cell helper phenotype expand in ACPA+ individuals during progression to rheumatoid arthritis
Ziyuan He¹, Marla Glass¹, Pravina Venkatesan², Alexandra Ferrannini³, Marie Feser⁴, Christy Bennett¹, David Boyle⁵, Kristen Demoruelle⁶, Kristine Kuhn⁷, Fan Zhang⁸, Thomas Bumol⁹, Ananda Goldrath³, Peter Skene³, V. Michael Holers¹⁰, Xiaojun Li¹, Adam Savage¹, Gary Firestein¹¹, Kevin Deane¹², Troy Torgerson¹³ and Mark Gillespie¹, ¹Allen Institute for Immunology, Seattle, WA, ²Allen Insitute, Seattle, WA, ³Allen Institute for Immunology, Seattle, ⁴University of Colorado Anschutz Medical Campus, Aurora, CO, ⁵UCSD, La Jolla, CA, ⁶University of Colorado Anschutz Medical Campus, Golden, CO, ⁷²⁰²² - ²⁰²³ / Adult/ University of Colorado, Aurora, CO, ⁸The University of Colorado, Aurora, CO, ⁹Allen Institute for Immunology, San Diego, CA, ¹⁰University of Colorado, Denver, CO, ¹¹University of California, San Diego, San Diego, CA, ¹²University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ¹³Allen Institute for Immunology, Enumclaw, WA
Background/Purpose: Prior to the onset of clinically apparent inflammatory arthritis (IA)/synovitis (clinical RA), ACPA+ ‘at-risk’ individuals (ARI) show alterations in the abundance of effector T…
Abstract Number: 0054 • ACR Convergence 2025
Microbial Cues Promote Arthritis and Alter T Cell Selection in SKG Mice
Astha Patel¹, Steven yu¹, Yuka Nakao¹, Mohana Mukherjee¹, Diego Orellana², Jose Scher³, Peter Turnbaugh¹, Renuka Nayak⁴ and Judith Ashouri¹, ¹University of California, San Francisco, San Francisco, CA, ²University of California San Francisco, San Francisco, CA, ³New York University School of Medicine, New York, NY, ⁴University of California, San Francisco (UCSF), San Francisco, CA
Background/Purpose: Dysbiosis of the gut microbiota has been linked to rheumatoid arthritis (RA), but it remains unclear whether these microbial alterations are causal or secondary…
Abstract Number: 1697 • ACR Convergence 2025
Dynamic Effects of T cell Engager Therapy on B and T cells in Autoimmune Disease.
Laura Bucci¹, Tobias Rothe², Ann-Kathrin Goetz³, Kirill Anoshkin¹, Danae-Mona Nöthling¹, Melanie Hagen¹, Sebastian Böltz¹, Andreas Wirsching¹, Georg Schett⁴ and Ricardo Grieshaber-Bouyer⁵, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ²Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlagen, Germany, ³Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, ⁴Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ⁵University Hospital Erlangen, Erlangen, Germany
Background/Purpose: Treatment of autoimmune disease with T cell engagers (TCEs) leads to profound peripheral B cell depletion, followed by their reconstitution. However, the dynamics of…
Abstract Number: 0991 • ACR Convergence 2025
MTHFD2 is a Novel Metabolic Target in Autoimmune Disease
Laura McMillan, Celia Evans, Marina Makrecka-Kuka, Niamh Richmond, Gareth Davies, Hamel Patel, Michael Herdman, Mark Whitmarsh, Alessandro Mazzacani, Peter Bunyard, Madduri Ravin Rao and Iain Kilty, Sitryx Therapeutics, Oxford, United Kingdom
Background/Purpose: Aberrant activation and persistence of adaptive immune responses play a central role in autoimmune pathogenesis. Where traditional immunosuppressive therapies offer a broad targeting approach,…
Abstract Number: 0887 • ACR Convergence 2025
Dynamics of cytotoxic and regulatory CD8 T cells underlies outcome in ICI-myotoxicity
Runci Wang¹, Chunyan Xiang², Adrien Procureur³, Julian Sanchez-Dal Cin³, Qing Wang⁴, Xinyue Lian⁵, Michelle Rosenzwajg³, Yves Allenbach⁶, Deepak Rao⁷, Qiong Fu⁸, Nan Shen⁹, Joe-Elie Salem³ and Shuang Ye¹⁰, ¹Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic), ²Shanghai Institute of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University (SJTUSM), shanghai, China (People's Republic), ³Sorbonne Université, Paris, France, ⁴Zhongshan Hospital, Shanghai, China (People's Republic), ⁵Renji Hospital, Shanghai, China (People's Republic), ⁶SORBONNE UNIVERSITE, Paris, France, ⁷Brigham and Women's Hospital, Boston, MA, ⁸Renji Hospital, Shanghai, Shanghai, China, ⁹Shanghai Jiang Tong University School of Medicine, Shanghai, China (People's Republic), ¹⁰Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai, Shanghai, China (People's Republic)
Background/Purpose: Immune checkpoint inhibitor (ICI) therapies for cancer can induce immune-related adverse events (irAEs) involving musculoskeletal (MSK) systems. ICI myotoxicity (ICI-M) can present as a…
Abstract Number: 0015 • ACR Convergence 2025
CDR111 is a novel CD19 and BCMA dual-targeting T cell engager (TCE) for the treatment of severe and refractory autoimmune diseases
Philipp Richle, Stephanie Jungmichel, Alessio Vantellini, André Fonseca, Anna Howald, Fabian Scheifele, Loredana iuliano, Ariadna Vilarrasa, Romina Doerig, Hannes Merten, Philip Knobel, Daniel Lenherr-Frey, Christian Leisner and Leonardo Borras, CDR-Life, Horgen, Zurich, Switzerland
Background/Purpose: B cells and plasma cells are central to the pathogenesis of many autoimmune diseases. While B cell depletion therapies (BCDTs), such as anti-CD20 monoclonal…
Abstract Number: 1653 • ACR Convergence 2025
Gut-joint lymphocyte trafficking functions to regulate systemic immunity
Sarah Danielson¹, Sucai Liu² and Kristine Kuhn³, ¹University of Colorado Anschutz Medical Campus, Aurora, ²University of Colorado School of Medicine, Aurora, CO, ³²⁰²² - ²⁰²³ / Adult/ University of Colorado, Aurora, CO
Background/Purpose: The gut-joint and mucosal origins hypotheses postulate that immune alterations in mucosal sites may precede and impact the development of rheumatoid arthritis and spondyloarthritis.…
Abstract Number: 0990 • ACR Convergence 2025
An Fc-engineered Agonistic Anti-PD-1 Antibody Selectively Depletes PD-1+ cells and Attenuates T cell activation in vitro and in vivo in a Xenogeneic Graft-versus-Host Disease (GvHD) model
laetitia Pouzol, Patrizia Murer, Nicole Egli, Laetitia Petersen, Anais Zurbach, christian Stocker, alexander Rau, andreas Katopodis and christoph huber, Anaveon, Basel, Switzerland
Background/Purpose: PD-1+ T cells play a pivotal role in the pathogenesis of autoimmune diseases, including rheumatoid arthritis. Therapeutic antibodies targeting PD-1 with both depleting and…
Abstract Number: 0886 • ACR Convergence 2025
A First-in-Class Biologic Selectively Targeting HLA-B27-Reactive T Cells in Ankylosing Spondylitis
Patrick Holec, Megan Reitars, Nishant Singh and Isabelle Larsen, Fletcher Biosciences, Cambridge, MA
Background/Purpose: Ankylosing spondylitis (AS), a chronic autoimmune disease strongly associated with HLA-B27:05, is currently managed with therapies that broadly suppress inflammation instead of targeting disease-driving…
Abstract Number: 0009 • ACR Convergence 2025
MRT-6160, a VAV1-Directed Molecular Glue Degrader, Attenuates T and B Cell Effector Functions and Inhibits Disease Progression in a Spontaneous MRL-Faslpr Mouse Model
Adam Cartwright¹, Lucas Gyger¹, Foram Desai², Shailee Vora², Anna Kostikova¹, Xudong Wang², Peter Trenh², Katie May², Sophia Nguyen², Chris King², Daniel Lam², Xavi Lucas¹, Mary Zlotosch², Elisa Liardo¹, Daric Wible², Ilaria Lamberto², Bradley Demarco², Debora Bonenfant¹, Sharon Townson², Eswar Krishnan², Filip Janku², John Castle¹, Laura McAllister¹, Alison Paterson² and Marisa Peluso², ¹Monte Rosa Therapeutics, Basel, Switzerland, ²Monte Rosa Therapeutics, Boston, MA
Background/Purpose: VAV1, an immune cell restricted guanine nucleotide exchange factor (GEF) and scaffolding protein, plays a critical role in mediating T- and B-cell receptor activity.…
Abstract Number: 1622 • ACR Convergence 2025
Defective CD4+ regulatory T cells in active Takayasu arteritis patients can be improved by efficiency treatment of tofacitinib
jing luo¹ and Lan He², ¹the first affiliated hospital of xi'an jiaotong university, xi'an, China (People's Republic), ²The First Affiliated Hospital of Xi’an Jiaotong University, Xi'an, China (People's Republic)
Background/Purpose: To investigate the efficacy of tofacitinib (TOF) in patients with active TAK, explore the effect on CD4+ regulatory T cells (Tregs) homeostasis and relationship…
Abstract Number: 0988 • ACR Convergence 2025
Distinct Effects of Inhibitory Receptor Agonism on RA Synovial CD4+ T Cell Functions
Kazuhiko Higashioka¹, John Sowerby¹, Kathryne Marks², Diana Pena-Nunez¹, Margaret Chang³, Jonathan Coblyn¹, Elena Massarotti¹, Brian Jones⁴, Ling-Yang Hao⁴, Navin Rao⁴ and Deepak Rao², ¹Brigham and Women's Hospital, Boston, ²Brigham and Women's Hospital, Boston, MA, ³Boston Children's Hospital, Boston, MA, ⁴Janssen Research & Development, Spring House
Background/Purpose: Autoreactive T cells play a crucial role in the autoimmune pathology of rheumatoid arthritis (RA). Activation of inhibitory receptors on T cells is a…
Abstract Number: 0885 • ACR Convergence 2025
MAIT cell-mediated immune modulation in lupus: antigen-driven expansion as a protective strategy
Grace Crossland¹, lennard Ostendorf², Vianey Chavez¹, Lindsay Mendyka¹, Deepak Rao³ and Sladjana Skopelja-Gardner¹, ¹Dartmouth College, Lebanon, NH, ²Brigham and Women's Hospital, Boston, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: Systemic lupus erythematosus (SLE) is a leading cause of death for young women, and over 75% of SLE patients experience skin manifestations – cutaneous…
Abstract Number: 0002 • ACR Convergence 2025
KITE-363: An Autologous Anti-CD19/CD20 CAR-T Product for the Treatment of Autoimmune Rheumatic Diseases
Brian Kim, Christine Lowe, Francisco Flores, Jeremy Margaitis, Alessandro Calo, Stacey Valny, Anna Konecny, Eva Jaghatspanyan, Sean Yoder, Kenneth Ertel, Simone Filosto, Jodi Murakami and David Barrett, Kite, a Gilead Company, Santa Monica, CA
Background/Purpose: B-cell dysregulation is a key factor in the development and progression of autoimmune diseases, and B-cell inhibition has been a cornerstone of treatment for…
Abstract Number: 1535 • ACR Convergence 2025
INB-619 – A Novel Gamma-Delta (γδ) T cell Engager to Target B cells in Autoimmune Diseases
Lei Ding, Yanjie Li, Mariska ter Haak, Sadhak Sengupta, Kate Rochlin and Lawrence Lamb, IN⁸bio, Inc., New York, NY
Background/Purpose: T cell engagers (TCEs) redirect T cells to bind target cells by linking T cells with target-associated antigens expressed on cells responsible for disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].